Naptumomab estafenatox
Naptumomab estafenatox is an antibody pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against trophoblast glycoprotein.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
5 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renal cell carcinoma | D002292 | 2 | 1 | 1 | — | — | 3 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | 3 | 1 | — | — | — | 4 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | — | — | — | — | 2 |
| Prostatic neoplasms | D011471 | C61 | 1 | — | — | — | — | 1 | |
| Colorectal neoplasms | D015179 | 1 | — | — | — | — | 1 | ||
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | — | — | — | 1 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | — | — | — | — | 1 |
| Triple negative breast neoplasms | D064726 | 1 | — | — | — | — | 1 | ||
| Endometrial neoplasms | D016889 | EFO_0004230 | 1 | — | — | — | — | 1 | |
| Urinary bladder neoplasms | D001749 | C67 | 1 | — | — | — | — | 1 | |
| Squamous cell carcinoma of head and neck | D000077195 | 1 | — | — | — | — | 1 | ||
| Melanoma | D008545 | 1 | — | — | — | — | 1 |
Show 2 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | NAPTUMOMAB ESTAFENATOX |
| INN | naptumomab estafenatox |
| Description | Naptumomab estafenatox (mouse Fab) |
| Classification | Antibody |
| Drug class | aptamers, classical and mirror; monoclonal antibodies |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 676258-98-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1743045 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB12807 |
| UNII ID | 93T929W6LC (ChemIDplus, GSRS) |
Target
Agency Approved
TPBG
TPBG
Organism
Homo sapiens
Gene name
TPBG
Gene synonyms
5T4
NCBI Gene ID
Protein name
trophoblast glycoprotein
Protein synonyms
5T4 oncofetal antigen, 5T4 oncofetal trophoblast glycoprotein, 5T4 oncotrophoblast glycoprotein, M6P1, WAIF1, Wnt-activated inhibitory factor 1
Uniprot ID
Mouse ortholog
Tpbg (21983)
trophoblast glycoprotein (Q9Z0L0)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 60 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
19 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more